The Effects of Modified Simiao Decoction in the Treatment of Gouty Arthritis: A Systematic Review and Meta-Analysis

Abstract EN

The modified Simiao decoctions (MSD) have been wildly applied in the treatment of gouty arthritis in China.

However, the evidence needs to be evaluated by a systematic review and meta-analysis.

After filtering, twenty-four randomised, controlled trials (RCTs) comparing the effects of MSD and anti-inflammation medications and/or urate-lowering therapies in patients with gouty arthritis were included.

In comparison with anti-inflammation medications, urate-lowering therapies, or coadministration of anti-inflammation medications and urate-lowering therapies, MSD monotherapy significantly lowered serum uric acid (p<0.00001, mean difference = −90.62, and 95% CI [−128.38, −52.86]; p<0.00001, mean difference = −91.43, and 95% CI [−122.38, −60.49]; p=0.02, mean difference = −40.30, and 95% CI [−74.24, −6.36], resp.).

Compared with anti-inflammation medications and/or urate-lowering therapies, MSD monotherapy significantly decreased ESR (p<0.00001; mean difference = −8.11; 95% CI [−12.53, −3.69]) and CRP (p=0.03; mean difference = −3.21; 95% CI [−6.07, −0.36]).

Additionally, the adverse effects (AEs) of MSD were fewer (p<0.00001; OR = 0.08; 95% CI [0.05, 0.16]).

MSD are effective in the treatment of gouty arthritis through anti-inflammation and lowering urate.

However, the efficacy of MSD should be estimated with more RCTs.